This mutation is situated within the DNA‐binding domain of the TP53 protein and is associated with impaired transcriptional activation, reduced proliferative suppression, and decreased Nrf2 expression, all of which may promote tumor cell proliferation [19]. This evidence concerns the gene TP53 and neoplasm.